Moderna Inc's stock rose after announcing positive Phase 3 trial results for its next-generation COVID-19 vaccine, MRNA-1283, and a $750 million investment from Blackstone Life Sciences for its flu program. The company's advancements in its mRNA vaccine pipeline were highlighted during its fifth Vaccines Day event, including the progression of multiple vaccine programs to late-stage clinical trials. MRNA-1283 showed a higher immune response than its licensed COVID-19 vaccine, and the investment will support the development of a combination flu and COVID-19 vaccine.